Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis

M. Fujáková, T. Páleníček, M. Brunovský, I. Gorman, F. Tylš, A. Kubešová, D. Řípová, V. Krajča, J. Horáček,

. 2014 ; 122 (-) : 212-221.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15014473

Grantová podpora
NT13897 MZ0 CEP - Centrální evidence projektů
NT13403 MZ0 CEP - Centrální evidence projektů

In the present study we investigated the potential antipsychotic effects of the mGlu2/3 agonist LY379268 on changes in EEG power spectra and coherence in the ketamine model of psychosis. In order to use behaviorally active drug doses, experiments detecting changes in locomotor activity and sensorimotor gating were also conducted. In EEG experiments, adult male Wistar rats were injected with ketamine 30 mg/kg i.p. and LY379268 3 mg/kg i.p. Cortical EEG was recorded from twelve (2 × 6) electrodes placed homolaterally on each hemisphere. To avoid interference with the behavioral hyperactivity of ketamine challenge, the behavioral activity of animals was simultaneously registered at the time of recording. Subsequent power spectral and coherence analyses were assessed in epochs corresponding to behavioral inactivity. Analysis of segments with behavioral activity compared to inactivity was also performed. The effects of LY379268 3 mg/kg i.p. on the deficits in sensorimotor processing and on hyperlocomotion induced by ketamine were evaluated in the test of prepulse inhibition of acoustic startle reaction (PPI ASR) and in the open field. LY379268 reversed the ketamine-induced hyperlocomotion but had no effect on ketamine-induced PPI deficits. In EEG epochs corresponding to behavioral inactivity ketamine decreased the power in the delta band, induced a power increase in the high frequency bands and globally decreased EEG coherence. Pretreatment with the LY379268 completely reversed the ketamine-induced power increase in high frequency bands and had a partial effect on EEG coherence. LY379268 alone induced a decrease of beta, high beta and low-gamma power, and an increase in coherence in high frequency bands. Additional analysis revealed that behavioral activity increases power as well as coherence in most frequency bands. In conclusion, agonism of mGlu2/3 receptors was effective in reversing most of the changes induced by ketamine, however due to the lack of effectiveness on PPI deficits its potential antipsychotic properties remain disputable.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014473
003      
CZ-PrNML
005      
20181026090803.0
007      
ta
008      
150420s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pbb.2014.03.001 $2 doi
035    __
$a (PubMed)24631484
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fujáková, Michaela $u Prague Psychiatric Center, Ústavní 91, 18103, Prague 8, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Ruská 87, 100 00 Prague 10, Czech Republic. Electronic address: fujakova@pcp.lf3.cuni.cz. $7 _AN027808
245    14
$a The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis / $c M. Fujáková, T. Páleníček, M. Brunovský, I. Gorman, F. Tylš, A. Kubešová, D. Řípová, V. Krajča, J. Horáček,
520    9_
$a In the present study we investigated the potential antipsychotic effects of the mGlu2/3 agonist LY379268 on changes in EEG power spectra and coherence in the ketamine model of psychosis. In order to use behaviorally active drug doses, experiments detecting changes in locomotor activity and sensorimotor gating were also conducted. In EEG experiments, adult male Wistar rats were injected with ketamine 30 mg/kg i.p. and LY379268 3 mg/kg i.p. Cortical EEG was recorded from twelve (2 × 6) electrodes placed homolaterally on each hemisphere. To avoid interference with the behavioral hyperactivity of ketamine challenge, the behavioral activity of animals was simultaneously registered at the time of recording. Subsequent power spectral and coherence analyses were assessed in epochs corresponding to behavioral inactivity. Analysis of segments with behavioral activity compared to inactivity was also performed. The effects of LY379268 3 mg/kg i.p. on the deficits in sensorimotor processing and on hyperlocomotion induced by ketamine were evaluated in the test of prepulse inhibition of acoustic startle reaction (PPI ASR) and in the open field. LY379268 reversed the ketamine-induced hyperlocomotion but had no effect on ketamine-induced PPI deficits. In EEG epochs corresponding to behavioral inactivity ketamine decreased the power in the delta band, induced a power increase in the high frequency bands and globally decreased EEG coherence. Pretreatment with the LY379268 completely reversed the ketamine-induced power increase in high frequency bands and had a partial effect on EEG coherence. LY379268 alone induced a decrease of beta, high beta and low-gamma power, and an increase in coherence in high frequency bands. Additional analysis revealed that behavioral activity increases power as well as coherence in most frequency bands. In conclusion, agonism of mGlu2/3 receptors was effective in reversing most of the changes induced by ketamine, however due to the lack of effectiveness on PPI deficits its potential antipsychotic properties remain disputable.
650    _2
$a aminokyseliny $x farmakologie $x terapeutické užití $7 D000596
650    _2
$a zvířata $7 D000818
650    _2
$a antipsychotika $x farmakologie $x terapeutické užití $7 D014150
650    _2
$a bicyklické sloučeniny heterocyklické $x farmakologie $x terapeutické užití $7 D019086
650    12
$a modely nemocí na zvířatech $7 D004195
650    _2
$a elektroencefalografie $x účinky léků $x metody $7 D004569
650    _2
$a ketamin $x toxicita $7 D007649
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a psychotické poruchy $x farmakoterapie $x patofyziologie $7 D011618
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a receptory metabotropního glutamátu $x agonisté $7 D018094
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Páleníček, Tomáš, $u Prague Psychiatric Center, Ústavní 91, 18103, Prague 8, Czech Republic. $d 1976- $7 mzk2004257555
700    1_
$a Brunovský, Martin, $u Prague Psychiatric Center, Ústavní 91, 18103, Prague 8, Czech Republic. $d 1975- $7 xx0070660
700    1_
$a Gorman, Ingmar $u Prague Psychiatric Center, Ústavní 91, 18103, Prague 8, Czech Republic. $7 _AN045561
700    1_
$a Tylš, Filip, $u Prague Psychiatric Center, Ústavní 91, 18103, Prague 8, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Ruská 87, 100 00 Prague 10, Czech Republic. $d 1985- $7 xx0218168
700    1_
$a Kubešová, Anna $u Prague Psychiatric Center, Ústavní 91, 18103, Prague 8, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Ruská 87, 100 00 Prague 10, Czech Republic. $7 _AN064719
700    1_
$a Řípová, Daniela, $u Prague Psychiatric Center, Ústavní 91, 18103, Prague 8, Czech Republic. $d 1953- $7 xx0091955
700    1_
$a Krajča, Vladimír $u Czech Technical University in Prague, Faculty of Biomedical Engineering, Nám. Sítná 3105, 272 01 Kladno, Czech Republic. $7 _AN096094
700    1_
$a Horáček, Jiří, $u Prague Psychiatric Center, Ústavní 91, 18103, Prague 8, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Ruská 87, 100 00 Prague 10, Czech Republic. $d 1966- $7 jo2002152353
773    0_
$w MED00003794 $t Pharmacology, biochemistry, and behavior $x 1873-5177 $g Roč. 122, č. - (2014), s. 212-221
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24631484 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20181026091314 $b ABA008
999    __
$a ok $b bmc $g 1072054 $s 897351
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 122 $c - $d 212-221 $i 1873-5177 $m Pharmacology, biochemistry and behavior $n Pharmacol Biochem Behav $x MED00003794
GRA    __
$a NT13897 $p MZ0
GRA    __
$a NT13403 $p MZ0
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...